Clinical Report: Effects of 25% Albumin Infusion on Intracranial Pressure Levels
Overview
This study evaluates the effects of 25% albumin infusion on intracranial pressure (ICP) in patients with severe brain injury. The findings indicate that 25% albumin does not exacerbate ICP in patients with elevated baseline levels.
Background
Intravenous fluid selection is critical in managing patients with severe brain injury, as it can influence ICP levels. Previous studies indicated that hypotonic albumin formulations were associated with higher mortality and ICP in traumatic brain injury (TBI) patients. This report investigates the impact of hyperoncotic 25% albumin on ICP.
Data Highlights
Parameter
Before Infusion
After Infusion
Median ICP (mmHg)
8 [IQR 7–17]
10 [IQR 8–14]
Median MAP (mmHg)
74.8 [71.8–82.8]
84.5 [74.1–93.2]
Key Findings
18 patients were analyzed, with a median ICP of 9 mmHg overall.
In patients with elevated ICP, median ICP decreased from 24 mmHg to 17.5 mmHg post-infusion (p = 0.106).
In patients with normal baseline ICP, median ICP increased slightly from 7.0 mmHg to 8.0 mmHg.
Median MAP increased from 74.8 mmHg to 84.5 mmHg after albumin administration.
27.8% of patients died during their hospital stay.
Findings align with prior data indicating ICP elevation only with hypotonic albumin formulations.
Clinical Implications
The study indicates that 25% albumin does not worsen ICP in patients with severe brain injury. However, the small sample size and lack of causal attribution to albumin necessitate cautious interpretation of these findings.
Conclusion
The infusion of 25% albumin appears to have a neutral effect on ICP levels. Further research is needed to confirm these observations.